Ratings by Guggenheim (Kelsey Goodwin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
113.75 (115.07) |
1.16% | Details | |
| 11/24/2025 | Arcellx Inc. | ACLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2025 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/23/2025 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2025 | Century Therapeutics | IPSC | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2024 | Genelux Corp. | GNLX | New Coverage | Buy (N/A) |
2.55 (2.91) |
14.12% | Details | |
| 8/22/2024 | UroGen Pharma | URGN | New Coverage | Buy (N/A) |
14.87 (35.16) |
136.45% | Details | |
| 7/31/2024 | MacroGenics | MGNX | Downgrade | Neutral (Buy) |
5.47 (4.60) |
-15.9% | Details | |
| 2/28/2024 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
86.61 (123.49) |
42.58% | Details | |
| 9/12/2023 | 2Seventy Bio Inc. | TSVT | Downgrade | Neutral (Buy) |
4.38 (5.00) |
14.16% | Details | |
| 10/31/2022 | Legand Biotech Corp. | LEGN | New Coverage | Neutral (N/A) |
49.56 (29.97) |
-39.53% | Details | |
| 10/31/2022 | Iovanace Biotherapeutics | IOVA | New Coverage | Neutral (N/A) |
9.75 (4.28) |
-56.1% | Details | |
| 10/31/2022 | 2Seventy Bio Inc. | TSVT | New Coverage | Buy (N/A) |
15.24 (5.00) |
-67.19% | Details | |
| 10/31/2022 | Century Therapeutics | IPSC | New Coverage | Buy (N/A) |
10.78 (2.41) |
-77.64% | Details | |
| 10/31/2022 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
22.01 (113.75) |
416.81% | Details |
